ArticleScience advances2022
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 57 citations in OpenAlex.
- ARHGAP40 suppresses clear cell renal cell carcinoma progression and is associated with altered glutamine-related metabolism and redox balance.Cancer biology & therapy · 2026Article
- Research progress in metabolic reprogramming and targeting metabolic pathways for clear cell renal cell carcinoma.Genes & diseases · 2026Review
- Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026Review
- Integrated multi-omics analysis reveals folate metabolism-related genes as prognostic markers and therapeutic targets in clear cell renal cell carcinoma.BMC cancer · 2026Article
- ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma.Cancer research · 2026Article
- Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma.Cell death & disease · 2026Article
- Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade.Journal of translational medicine · 2026Article
- HIF2α inhibits glutaminase clustering in mitochondria to sustain growth of clear cell renal cell carcinoma.JCI insight · 2025Article
- TKT drives renal cell carcinoma progression through metabolic reprogramming and synergistic interaction with PKM2.Cell death discovery · 2025Article
- Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.Nature communications · 2025Article
- Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis.bioRxiv : the preprint server for biology · 2025Article
- Methods and Guidelines for Metabolism Studies: Applications to Cancer Research.International journal of molecular sciences · 2025Review
- The RNA demethylase FTO promotes glutamine metabolism in clear cell renal cell carcinoma through the regulation of SLC1A5.Science advances · 2025Article
- Autophagy and the peroxisome proliferator-activated receptor signaling pathway: A molecular ballet in lipid metabolism and homeostasis.Molecular and cellular biochemistry · 2025Review
- Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma.Cell reports · 2025Article
- Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches.Cell reports · 2025Review
- The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma.Cell death discovery · 2025Review
- Metabolic Dialogue Shapes Immune Response in the Tumor Microenvironment.European journal of immunology · 2025Review
- Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Metabolic signatures in gastroenteropancreatic neuroendocrine neoplasms: unraveling diagnostic and prognostic insights.Frontiers in endocrinology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
29 authors at 10 institutions in 3 countries.
Akash K KaushikChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-8200-2370
Amy TarangeloChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-0571-3582
Lindsey K BoroughsChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Mukundan RagavanDepartment of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-8678-4229
Yuanyuan ZhangChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Cheng-Yang WuDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xiangyi LiChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-6157-8047
Kristen AhumadaChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jui-Chung ChiangChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9979-8347
Vanina T TcheuyapKidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-6817-9241
Faeze SaatchiKidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9151-7133
Quyen N DoDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9511-7866
Cissy YongDepartment of Surgery, University of Cambridge, Cambridge, UK.ORCID 0000-0002-8697-1494
Tracy RosalesChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-7285-2427
Christina StevensKidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Aparna D RaoPeter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.ORCID 0000-0002-6394-0011
Brandon FaubertDepartment of Medicine, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-2886-886X
Panayotis PachnisChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-3019-7874
Lauren G ZachariasChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hieu VuChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Feng CaiChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Thomas P MathewsChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-9355-8243
Giannicola GenoveseDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Barbara S SlusherDepartment of Neurology and Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9814-4157
Payal KapurKidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xiankai SunDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-5140-6110
Matthew MerrittDepartment of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-4617-9651
James BrugarolasKidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-8575-499X
Ralph J DeBerardinisChildren's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-2705-7432
The University of Texas Southwestern Medical Center · USAdvanced Imaging Research (United States) · USHoward Hughes Medical Institute · USJohns Hopkins University · USSt. Jude Children's Research Hospital · USThe University of Melbourne · AUThe University of Texas MD Anderson Cancer Center · USUniversity of Cambridge · GBUniversity of Chicago · USUniversity of Florida · US
Funding
University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7MMetabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4MUT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI JOEL K. ELMQUIST · 2022 to 2026
$7.4MTR&D3-SCHP41GM122698 · NIGMS · FLORIDA STATE UNIVERSITY · PI BREY, WILLIAM W, CROSS, TIMOTHY A · 2017 to 2021
$6.7MUT Southwestern Center for Translational MedicineKL2TR003981 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI ARGENBRIGHT, KEITH EDWARD, TRIVEDI, MADHUKAR H. · 2021 to 2025
$5.9MCell-targeted glutamine antagonists as a novel therapy for lymphomaR01CA229451 · NCI · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH · 2018 to 2022
$2.3MImaging Hepatic Energy Metabolism in NAFLD/NASHR01DK132254 · NIDDK · UNIVERSITY OF FLORIDA · PI MERRITT, MATTHEW E · 2022 to 2025
$2.0MImaging Hepatic Gluconeogenesis with Hyperpolarized DihydroxyacetoneR01DK105346 · NIDDK · UNIVERSITY OF FLORIDA · PI MERRITT, MATTHEW E · 2016 to 2020
$1.7MIdentifying factors regulating cancer metabolism in vivoR00CA237724 · NCI · UNIVERSITY OF CHICAGO · PI FAUBERT, BRANDON · 2022 to 2024
$667kNMR console upgrade for structural biology and metabolomicsS10OD028753 · OD · UNIVERSITY OF FLORIDA · PI LONG, JOANNA R · 2020 to 2020
$600kQuantitative magnetic resonance imaging and automated textural radiomics for assessment of human placenta accreta spectrumK25HD104004 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI DO, QUYEN NGOC · 2020 to 2024
$570kInvestigating the Role of Metabolic Reprogramming in Cancer Cell Death SensitivityK00CA234650 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TARANGELO, AMY · 2020 to 2022
$278kNCATS NIH HHS KL2 TR003981NCI NIH HHS K00 CA234650NCI NIH HHS P50 CA196516NCI NIH HHS R00 CA237724NCI NIH HHS R01 CA229451NCI NIH HHS R35 CA220449NICHD NIH HHS K25 HD104004NIDDK NIH HHS P30 DK127984NIDDK NIH HHS R01 DK105346NIDDK NIH HHS R01 DK132254NIGMS NIH HHS P41 GM122698NIH HHS S10 OD028753
Abstract
Targeting metabolic vulnerabilities has been proposed as a therapeutic strategy in renal cell carcinoma (RCC). Here, we analyzed the metabolism of patient-derived xenografts (tumorgrafts) from diverse subtypes of RCC. Tumorgrafts from
Indexed as
Carcinoma, Renal CellKidney NeoplasmsAnimalsGlutaminaseGlutamineHumansIsocitrate DehydrogenaseMiceGlutaminaseGlutamineIsocitrate Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.